7EYA.F · EyeGate Pharmaceuticals, Inc

-

Please sign in to comment on 7EYA.F

1 Comment

Admin

4 years ago

EyeGate Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 24.3% below its 200 day moving average.

From a valuation standpoint, the stock is 43.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1877.8.

EyeGate Pharmaceuticals, Inc's total revenue rose by inf% to $12K since the same quarter in the previous year.

Its net income has increased by 10.6% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 33.1% to $-2M since the same quarter in the previous year.

Based on the above factors, EyeGate Pharmaceuticals, Inc gets an overall score of 3/5.

ISIN	None
Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR

Beta	1.12
Market Cap	21M
PE Ratio	None
Target Price	10.25
Dividend Yield	None

ABOUT

EyeGate Pharmaceuticals, Inc

Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States. Its pipeline includes KIO-101, a small molecule DHODH inhibitor that treats immunologic eye diseases; KIO-201, an eye drop that enhances ocular wound healing and protects the ocular surface; and KIO-301, a small molecule that has the potential to restore vision in patients with inherited or age related retinal degeneration. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is based in Salt Lake City, Utah.

7EYA.F · EyeGate Pharmaceuticals, Inc

-

EyeGate Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest EyeGate Pharmaceuticals, Inc using a moving average strategy